

TRACKING MIS-C: Multi-System Inflammatory Syndrome in U.S. Children

186 MIS-C CASES

26 STATES



MARCH 15 – MAY 20, 2020

Epidemiology of MIS-C


Hospital-reported MIS-C Cases by State

Number of cases identified in reporting states

- States not reporting
- 1-6
- 7-14
- 15-21
- 22-29



By leveraging a national influenza surveillance network of pediatric ICUs¹, CDC and partners conducted targeted surveillance for MIS-C from March 15 through May 20, 2020, identifying 186 MIS-C cases in 26 states.




Percentage of U.S. Children with MIS-C, by race and ethnicity*




*Race categories were non-exclusive

CASES MET 5 CRITERIA


- Hospitalized patients < 21 years
- Fever ≥ 24 hours
- Laboratory evidence of inflammation
- ≥ 2 organs involved
- Evidence of SARS-CoV-2² by RT-PCR³, antibody test, or exposure to person with COVID-19 in the prior month



Impact on Other Organs, by Age



Percentage of MIS-C Patients with Laboratory Evidence of Inflammation, by Age



Treatment	Highest Level of Care	Outcomes
Intravenous Immunoglobulin (IVIg) 77%	Ward 20%	Median Hospitalization 7 days
Second dose IVIg 21%	Intensive Care Unit 80%	Still Hospitalized May 20, 2020 28%
Systemic Steroids 49%	Intensive Care Interventions	Discharged Alive 70%
IL-6 Inhibitors (tocilizumab and siltuximab) 8%	ECMO ⁹ 4%	Died 2%
IL-1Ra Inhibitor (anakinra) 13%	Mechanical Ventilation 20%	
Systemic Anticoagulation 47%	Vasoactive Support 48%	

Percentage of U.S. MIS-C Patients with Features of Kawasaki Disease (KD) and Other Diseases

	4-5 KD FEATURES	2-3 KD FEATURES + LABS	Other FEATURES*	No KD FEATURES
CHARACTERISTICS	20%	19%	61%	100%
Age (years)	8.9	12.0	14.1	12.5
Fever > 38 C°	100	100	100	100
Bilateral Conjunctivitis	95	83	33	55
Oral Mucosal Changes	100	44	21	42
Peripheral Extremity Changes	95	39	17	37
Rash	100	75	40	59
Cervical Lymphadenopathy	18	8	7	10
Z-Score of LAD or RCA ≥ 2.5**	8	22	4	9

**among those with echocardiograms (n=170)

*This category includes patients who had 0 or 1 Kawasaki disease-like features or 2 or 3 features without additional laboratory findings.

ABBREVIATIONS

- ¹Intensive Care Unit (ICU)
- ²Acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- ³Reverse transcription polymerase chain reaction (RT-PCR)
- ⁴Cardiovascular intervention (CVI)
- ⁵Left anterior descending artery (LAD)
- ⁶Right coronary artery (RCA)
- ⁷Extracorporeal membrane oxygenation (ECMO)
- ⁸Deep vein thrombosis (DVT)
- ⁹Fibrinogen equivalent units (FEU)
- ¹⁰International normalized ratio (INR)
- ¹¹Erythrocyte sedimentation rate (ESR)
- ¹²Alanine aminotransferase (ALT)

